Examiner: HAM, JIEUN

Tech Center 1600 • Art Units: 1600 1643 1652

This examiner grants 50% of resolved cases

Performance Statistics

50.0%

Allow Rate

-10.0% vs TC avg

Total Applications

+62.5%

Interview Lift

1027

Avg Prosecution Days

Based on 6 resolved cases, 2023–2026

1.0%

§101 Eligibility

15.5%

§102 Novelty

32.0%

§103 Obviousness

27.8%

§112 Clarity

App #	Title	Status	Assignee
17904473	CHIMERIC SCAVENGER RECEPTORS TARGETED TO PHOSPHORYLATED TAU (PTAU) AND USES THEREOF	Non-Final OA	Board of Regents, The University of Texas System
17611019	METHODS AND COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER	Non-Final OA	Board of Regents, The University of Texas System
18577912	DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF MYASTHENIA GRAVIS	Non-Final OA	Alexion Pharmaceuticals, Inc.

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.